Member Info for busters

Disco, from memory she stated analysts forecasts, i think for the end of the year, would be between 18 and 19 million.

Robid's memory could be better than mine so his recollection may be better.

Just watched again yesterdays results video and Angela's reference to analysts 18 to 19 million has disappeared completely, wiped from the video.

By the look JB gave her this was obviously sensitive information not to be disclosed, how strange.

Robid's early post yesterday mentioned this figure as well so confirms I am not imagining it.

Hi robid,

did you notice the look JB gave Angela when she released these figures ? I think she may have jumped the gun.

81 lucky.

Eroxon was available to be prescribed on the NHS from March this year

Thanks desoc, because Haleon had not RNS'd it I assumed Futura was ahead of Haleon.

Was not aware of the FT article.

Monday's RNS was not expected to be issued by Futura as, when questioned, JB always said any American launch date would be announced by Haleon not Futura.

Wishful thinking perhaps but if the company can get the share price higher by doing this then any possible takeover offer would also have to be at a higher price. Hopefully, Tuesday's results will add more meat to the bones.

Thankfully, lack of cash is not a problem, 7.7 million at end of 2023

I assume the share price drop today could be linked to Destiny pharma going into administration .

Generally the norm is when board members are awarded shares free of charge, some of these are immediately sold to cover tax and NI liabilities.

Adolfo made the decision to pay these out of his own funds rather than reduce his holding, what a show of confidence in the company !

As the old saying goes,

Turnover is vanity, profit is sanity.

Haleon's next trading update is October so Eroxon launch could possibly be announced as early as then.

Just of interest, it is ironic that Haleon, the forthcoming distributor in the USA, has had a steadily increasing share price from 220 to 240, while the share price of its future supplier has had a steadily decreasing share price.

Times tonight, article Headed "ATOS warns of material uncertainty over future of British arm".

It has warned in its accounts there is "material uncertainty" about its ability to continue as a going concern.

DD ,

This was my question to Investor Relations on May 2nd, no response, repeated my request again this week, no response.

What is the point of having Investor Relations who appear to not want a relationship with small investors. Maybe they only want to have a relationship with institutional investors, can you imagine their reaction if they were repeatedly ignored.

All credit for Finnish news must go to milktrayman, I only copied and pasted it to Investor relations

Although the CEO stated the company has no control over the share price, it can issue news items which helps sentiment and supports the share price.

Why doesn't the company issue Reach RNS's when positive news is announced by its distributors such as the recent one for Norway......

“The successful launch in Norway of Eroxon® in February was an important and significant event. After only two weeks in the market, this clinically proven local treatment of erectile dysfunction was the bestseller at an online pharmacy. Strong sales in the rest of the first quarter, resulted in Eroxon® ranking third on Navamedic’s most sold products in the Consumer Health segment. Eroxon® will be launched in Sweden in May, and in Finland later this year,” said Kathrine Gamborg, CEO of Navamedic ASA.

https://news.cision.com/navamedic-asa/r/navamedic-q1-2024--successful-product-launch-and-steady-operational-progress,c3970410

Snippets of news like this would go a long way to underpin the share price rather than allow the constant drip, drip downwards. Private investors cannot allow their savings to reduce day after day so consequently have to limit their losses by selling where as Institutional investors hold for the long term. What is the company doing to attract more Institutional investors ?

Hoping you will pass this on to the board, I look forward to hearing their response

Sent to Investor relations today.

In the recent podcast the CEO stated the company has no control of the share price.

I agree they cannot control it but surely they could help it by announcing when distribution begins in new markets such as kdonkey100 reported the Portuguese website is now up and running.

It seems to appear the company want to have a low valuation for some reason or another.

Market report in the Mail this morning puts a negative slant on the results .

"Consumer healthcare firm Futura Medical warned there was some uncertainty over its ability to generate revenue and the timing of key milestone payments.

Last year it made £3.1million following the launch of a gel to treat erectile dysfunction. But it said it was difficult to predict future sales."

It fell 13.6 per cent, or 5.8p, to 37p.

I was wrong thinking the 10 new countries would be announced this week so guess they will let us know with the results.

"with full launches in at least ten countries including key European markets such as France, Italy and Spain remaining on track to take place before April 2024. "

News next week all being well.